Research map: Non-invasive tests for the evaluation of liver fibrosis in MASLD

Papers in this map

1. Design and validation of a histological scoring system for nonalcoholic fatty liver disease† · David Erwin Kleiner · 2005 · 10909 citations · Cited by this paper
2. Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial · 2026 · Related
3. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention · Zobair M. Younossi · 2017 · 5363 citations · Cited by this paper
4. Human embryonic stem cell-derived dopaminergic cells for Parkinson’s disease: a phase 1/2 open-label trial · 2026 · Related
5. The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease · Timothy Hardy · 2020 · 140 citations · Cited by this paper
6. FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial · 2026 · Related
7. Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol · Michael Pavlides · 2023 · 15 citations · Cited by this paper
8. Data rights are the missing pillar for modernizing consent in medicine · 2026 · Related
9. Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection · 2026 · Related
10. Multi-omics maps human–pig interactions in extracorporeal liver cross-circulation · 2026 · Related
11. Oligonucleotide–siRNA conjugate for SOD1 amyotrophic lateral sclerosis: a phase 1 trial · 2026 · Related
12. The genetic architecture of fibromyalgia across 2.5 million individuals · 2026 · Related
13. Individualized antisense oligonucleotides for SCN2A-related developmental epileptic encephalopathy · 2026 · Related
14. Early detection of Alzheimer’s disease with circular RNA from blood · 2026 · Related

Source: OpenAlex (CC0)